Halozyme Therapeutics Inc. is a NASDAQ listed security that has been trading in a range between $2.15 and $11.00 over the past year. With 71,944,190 shares outstanding, a recent price of $8.01 gives a total market capitalization of $589,222,886. While there are certainly larger companies, Halozyme Therapeutics Inc. has definitely earned its place in the pack. Last year, Halozyme Therapeutics Inc. created $-0.22 in earnings for every share outstanding.
Halozyme Therapeutics Inc. is currently priced by the market at 0.00 times last year’s earnings. Many trading multiples around the world are quite attractive these days, but don’t be fooled. A Price to Earnings ratio of 0 simply means that the security didn’t make any money last year.
With a share price under $50 a share and earnings per share below $1 a share, Halozyme Therapeutics Inc. is unlikely to be an interesting value proposition. Consistent earnings are the key to high valuations and this security is not on its way.
Subscribe to:
Post Comments (Atom)
1 comments:
Erasmus speaks mysterious language.
I favor Spinoza. Still, Halozyme looks good to me.
Post a Comment